BACKGROUND: Antagonizing the production of infectious virus inside cells requires drugs that can cross the cell membrane without harming host cells. OBJECTIVE: It is therefore advantageous to establish intracellular potency of anti-viral drug candidates early in the drug-discovery pipeline. METHODS: To this end, cell-based assays are being developed and employed in high-throughput drug screening, ranging from assays that monitor replication of intact viruses to those that monitor activity of specific viral proteins. While numerous cell-based assays have been developed and investigated, rapid counter screens are also needed to define the specific viral targets of identified inhibitors and to eliminate nonspecific screening hits. RESULTS/ CONCLUSIONS: Here, we describe the types of cell-based assays being used in antiviral drug screens and evaluate the equally important counter screens that are being employed to reach the full potential of cell-based high-throughput screening.
BACKGROUND: Antagonizing the production of infectious virus inside cells requires drugs that can cross the cell membrane without harming host cells. OBJECTIVE: It is therefore advantageous to establish intracellular potency of anti-viral drug candidates early in the drug-discovery pipeline. METHODS: To this end, cell-based assays are being developed and employed in high-throughput drug screening, ranging from assays that monitor replication of intact viruses to those that monitor activity of specific viral proteins. While numerous cell-based assays have been developed and investigated, rapid counter screens are also needed to define the specific viral targets of identified inhibitors and to eliminate nonspecific screening hits. RESULTS/ CONCLUSIONS: Here, we describe the types of cell-based assays being used in antiviral drug screens and evaluate the equally important counter screens that are being employed to reach the full potential of cell-based high-throughput screening.
Authors: R Pauwels; J Balzarini; M Baba; R Snoeck; D Schols; P Herdewijn; J Desmyter; E De Clercq Journal: J Virol Methods Date: 1988-08 Impact factor: 2.014
Authors: Laura K White; Jeong-Joong Yoon; Jin K Lee; Aiming Sun; Yuhong Du; Haian Fu; James P Snyder; Richard K Plemper Journal: Antimicrob Agents Chemother Date: 2007-04-30 Impact factor: 5.191
Authors: Lee F Peng; Sun Suk Kim; Sirinya Matchacheep; Xiaoguang Lei; Shun Su; Wenyu Lin; Weerawat Runguphan; Won-Hyeok Choe; Naoya Sakamoto; Masanori Ikeda; Nobuyuki Kato; Aaron B Beeler; John A Porco; Stuart L Schreiber; Raymond T Chung Journal: Antimicrob Agents Chemother Date: 2007-08-06 Impact factor: 5.191
Authors: Paul Zuck; Edward M Murray; Erica Stec; Jay A Grobler; Adam J Simon; Berta Strulovici; James Inglese; Osvaldo A Flores; Marc Ferrer Journal: Anal Biochem Date: 2004-11-15 Impact factor: 3.365
Authors: Pedro N Batalha; Luana S M Forezi; Carolina G S Lima; Fernanda P Pauli; Fernanda C S Boechat; Maria Cecília B V de Souza; Anna C Cunha; Vitor F Ferreira; Fernando de C da Silva Journal: Bioorg Chem Date: 2020-11-19 Impact factor: 5.275
Authors: Francesco Costacurta; Stephan Geley; Seyad Arad Mogadashi; Andre Volland; Emmanuel Heilmann; Bernhard Rupp; Reuben Stewart Harris; Dorothee von Laer Journal: Commun Biol Date: 2022-04-27
Authors: Richard T Eastman; Jacob S Roth; Kyle R Brimacombe; Anton Simeonov; Min Shen; Samarjit Patnaik; Matthew D Hall Journal: ACS Cent Sci Date: 2020-05-04 Impact factor: 14.553
Authors: Min Gao; Richard E Nettles; Makonen Belema; Lawrence B Snyder; Van N Nguyen; Robert A Fridell; Michael H Serrano-Wu; David R Langley; Jin-Hua Sun; Donald R O'Boyle; Julie A Lemm; Chunfu Wang; Jay O Knipe; Caly Chien; Richard J Colonno; Dennis M Grasela; Nicholas A Meanwell; Lawrence G Hamann Journal: Nature Date: 2010-04-21 Impact factor: 49.962